PD-L2 based immune signature confers poor prognosis in HNSCC
Yu Qiao, Chao Liu, Xiaoyue Zhang, Qianqian Zhou, Yatian Li, Yini Xu, Zhenyue Gao, Yiqi Xu, Lingping Kong, Aifeng Yang, Mei Mei, Yu Ren, Xudong Wang, Xuan Zhou
Abstract
to a median OS of 10 months and PI of 1.43 (95% CI, 0.56 to 2.30). Analysis of single-cell RNA sequencing showed that PD-L2 expression was associated with IL-6 expression. We confirmed that IL-6 augments PD-L2 expression in HNSCC cell lines. The PD-L2-based immune signature can serve as an effective biomarker for anti-PD-1 therapy. In addition, PD-L2 may serve as a potential immunotherapeutic target, and we propose anti-IL6 therapy in the adjuvant setting for patients with HNSCC with high PD-L2 expression.
Topics & Concepts
MedicineHead and neck squamous-cell carcinomaOncologyBiomarkerInternal medicineImmune systemAdjuvantPD-L1ImmunotherapyAdjuvant therapyCancer researchCancerImmunologyHead and neck cancerBiologyBiochemistryCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisImmune cells in cancer